"The U.S. Food and Drug Administration today approved Vimizim (elosulfase alfa), the first FDA-approved treatment for Mucopolysaccharidosis Type IVA (Morquio A syndrome). Morquio A syndrome is a rare, autosomal recessive lysosomal storage disease "...
Before administering Neotrace®-4 in TPN solutions, the physician must assess the metabolic requirements of trace elements and disease state of the patient. Frequent determinations of serum levels of the four trace elements are suggested as a guideline for adjusting the dosage or completely omitting Neotrace®-4. Zinc is eliminated via the intestine and kidneys; copper and manganese are eliminated via the bile; and chromium primarily via the kidneys. The possibility of their retention should be considered in patients with malfunctioning excretory routes of the respective trace elements.
Syringes equipped with aluminum needles or hubs should not be used, as the solution is acidic.
Category C: Animal reproduction studies have not been conducted with Neotrace®-4. It is also not known whether Neotrace®-4 can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Neotrace®-4 should be given to a pregnant woman only if clearly needed.
Last reviewed on RxList: 12/8/2004
This monograph has been modified to include the generic and brand name in many instances.
Additional Neotrace-4 Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.